News Headlines Article

FDA approves $84,000-a-treatment heptatitis C drug
Modern Healthcare

U.S. health officials have approved a highly anticipated hepatitis C drug from Gilead Sciences that is expected to offer a faster, more palatable cure to millions of people infected with the liver-destroying virus.

The Food and Drug Administration said Friday it approved the pill Sovaldi in combination with older drugs to treat the main forms of hepatitis C that affect U.S. patients.

Current treatments for hepatitis C can take up to a year of therapy and involve weekly injections of a drug that causes flu-like side effects. That approach only cures about three out of four patients.

Commands